Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 4/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | PPARD | Q03181 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7795595 | 0.90 | L3MBTL1 (0.39) | MAPTLTA4HPTPN1L3MBTL1TDP1 | |
| SCHEMBL7799028 | 0.90 | MAPT (0.37) | MAPTSMN1; SMN2LTA4HPTPN1BRD4 | |
| SCHEMBL7795476 | 0.86 | AR (0.35) | SMN1; SMN2TSHRFFAR1FFAR4 | |
| SCHEMBL7795186 | 0.77 | MEN1 (0.38) | SMN1; SMN2BRD4TSHR | |
| SCHEMBL7799040 | 0.74 | MEN1 (0.43) | MAPTPTPN1BRD4TSHRL3MBTL1 | |
| SCHEMBL7294390 | 0.68 | LTA4H (0.53) | MAPTSMN1; SMN2LTA4HL3MBTL1TDP1 | |
| SCHEMBL7752657 | 0.68 | PRSS1 (0.61) | MAPT | |
| SCHEMBL27543472 | 0.68 | PPARA (0.51) | PPARATSHRL3MBTL1FFAR1FFAR4 | |
| Iodide SCHEMBL7752650 | 0.67 | PRSS1 (0.59) | MAPT | |
| Hydrochloric Acid SCHEMBL7753379 | 0.67 | PPARA (0.50) | PPARATSHRL3MBTL1FFAR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010012901-A1 | Sulphonyl compounds for use as linkers in solid phase and combinatorial synthesis | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2001-08-09 | — | — | US | disclosed |
| US-6225480-B1 | FOR SYNTHESIS OF ORGANIC COMPOUNDS CONTAINING--NH--GROUPS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-05-01 | — | — | US | disclosed |
| EP-0948480-A1 | SULPHONYL COMPOUNDS FOR USE AS LINKERS IN SOLID PHASE AND COMBINATORIAL SYNTHESIS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-10-13 | — | — | EP | disclosed |
| WO-1998029386-A1 | SULPHONYL COMPOUNDS FOR USE AS LINKERS IN SOLID PHASE AND COMBINATORIAL SYNTHESIS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010012901-A1 | Sulphonyl compounds for use as linkers in solid phase and combinatorial synthesis | H1-0, H1-2, ASH2L | MAPT 3715/4885SMN1; SMN2 681/4885LTA4H 1359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.